Wedbush Reiterates Outperform on Edgewise Therapeutics, Maintains $31 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico has reiterated an Outperform rating on Edgewise Therapeutics (NASDAQ:EWTX) and maintained a $31 price target.
August 16, 2024 | 4:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Laura Chico has reiterated an Outperform rating on Edgewise Therapeutics and maintained a $31 price target.
The reiteration of an Outperform rating and a maintained price target of $31 by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100